What did the Nureca board approve at its meeting?

The board approved the company's audited financial results for FY25 and various annexures. These were already announced in a prior filing, so the numbers carry no surprise.

Who is the new director, and what role did she take?

Ms. Smita Goyal was appointed as a Whole-Time Director. This is a key operational role, not an independent board seat.

Were there any other management changes?

Yes, the board also re-appointed key management personnel in the same meeting, though the filing does not specify who or in what roles.

Is there any new financial information in this filing?

No. The rationale states the core financial results were previously disclosed. This filing is the detailed annexure to that announcement.

Earnings · Medical Equipment · Micro cap

Nureca posts FY25 results and adds a whole-time director

The board meeting results were already flagged. The new detail is a governance shift at the nano-cap.

— 3 earlier stories on Nureca Ltd. →

NURECA By Tipsheet Editorial 29 May 2026 · 9:55 PM IST Verify on BSE · NSE

Mkt cap₹221 cr

P/E106.23×

ROE0.44%

Debt / eq.0.01

FY25 results Audited annual results already disclosed in a prior filing.

What's new

Board approved FY25 audited financial results and annexures at a meeting.
Ms. Smita Goyal was appointed as a Whole-Time Director.
Key management personnel were re-appointed in the same meeting.

Why this matters

The results themselves are old news. The real filing content is the new director appointment. For a nano-cap, adding a whole-time director changes the governance setup and signals a shift in day-to-day management responsibility.

What we're watching

Ms. Goyal's role and mandate as the new Whole-Time Director.
Any changes to the company's strategic direction post-appointment.
Whether the core business shows any momentum in upcoming quarters.

The full read

Nureca's board approved its FY25 audited results. This was already known. The new detail is a governance move: Ms. Smita Goyal joined as a Whole-Time Director, and other key management roles were re-appointed. For a nano-cap, adding a full-time executive director is the kind of internal shift that matters more than numbers the market already has. The business itself remains on watch. What changes from here is how the new directorship shapes strategy.

Questions answered

What did the Nureca board approve at its meeting?: The board approved the company's audited financial results for FY25 and various annexures. These were already announced in a prior filing, so the numbers carry no surprise.
Who is the new director, and what role did she take?: Ms. Smita Goyal was appointed as a Whole-Time Director. This is a key operational role, not an independent board seat.
Were there any other management changes?: Yes, the board also re-appointed key management personnel in the same meeting, though the filing does not specify who or in what roles.
Is there any new financial information in this filing?: No. The rationale states the core financial results were previously disclosed. This filing is the detailed annexure to that announcement.

Mentioned: Ms. Smita Goyal · Whole-Time Director

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on NURECA →

29 May 2026 · 9:55 PM IST Nureca posts FY25 results and adds a whole-time director
today Nureca promoter buys 60,842 shares, nudging stake to 34.35%
8d ago Nureca raised its Punjab plant budget 28%. It calls the first number a typo.
11d ago Nureca's ₹100 cr capex is 37% of its market cap. The CFO is leaving.